RNA interference for cancer therapies

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 11, 2010, Pages 2033-2041

  Ashihara, Eishi ^a,b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cancer therapy; Drug delivery system (DDS); RNA interference; siRNA

Indexed keywords

POLO LIKE KINASE 1; SMALL INTERFERING RNA;

ANGIOGENESIS; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; METASTASIS; MITOSIS; REVIEW; RNA INTERFERENCE;

EID: 79961194025     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Meister G and Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349, 2004. (Pubitemid 39265674)
2. Yano J, Hirabayashi K, Nakagawa S, et al: Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 10: 7721-7726, 2004. (Pubitemid 39557537)
3. Urban-Klein B, Werth S, Abuharbeid S, et al: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12: 461-466, 2005. (Pubitemid 40394299)
4. Nogawa M, Yuasa T, Kimura S, et al: Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217: 243-253, 2005. (Pubitemid 40023124)
5. Kawata E, Ashihara E, Kimura S, et al: Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther 7: 2904-2912, 2008.
6. Thomas CE, Ehrhardt A and Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-358, 2003. (Pubitemid 36538359)
7. Check E: A tragic setback. Nature 420: 116-118, 2002.
8. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256, 2003. (Pubitemid 36077924)
9. Napoli C, Lemieux C and Jorgensen R: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2: 279-289, 1990. (Pubitemid 120029588)
10. van der Krol AR, Mur LA, Beld M, et al: Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell 2: 291-299, 1990. (Pubitemid 120029589)
11. Fire A, Albertson D, Harrison SW, et al: Production of antisense RNA leads to effective and specific inhibition of gene expression in C. elegans muscle. Development 113: 503-514, 1991.
12. Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998. (Pubitemid 28099681)
13. Bernstein E, Caudy AA, Hammond SM, et al: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409: 363-366, 2001. (Pubitemid 32151243)
14. Elbashir SM, Martinez J, Patkaniowska A, et al: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 20: 6877-6888, 2001. (Pubitemid 33134217)
15. Hammond SM, Bernstein E, Beach D, et al: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-266, 2000.
16. Ashihara E, Kawata E and Maekawa T: Future prospect of RNA interference for cancer therapies. Curr Drug Targets 11: 345-360, 2010.
17. Esquela-Kerscher A and Slack FJ: Oncomirs- micro- RNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
18. Krek A, Grun D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.
19. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002. (Pubitemid 35403967)
20. Zhang B, Pan X, Cobb GP, et al: microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12, 2007.
21. Winkles JA and Alberts GF: Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24: 260-266, 2005.
22. Barr FA, Sillje HH and Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5: 429-440, 2004. (Pubitemid 38745493)
23. van de Weerdt BC and Medema RH: Polo-like kinases: a team in control of the division. Cell Cycle 5: 853-864, 2006.
24. Knecht R, Elez R, Oechler M, et al: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59: 2794-2797, 1999. (Pubitemid 29283110)
25. Strebhardt K, Kneisel L, Linhart C, et al: Prognostic value of pololike kinase expression in melanomas. JAMA 283: 479-480, 2000. (Pubitemid 30062860)
26. Wolf G, Elez R, Doermer A, et al: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14: 543-549, 1997. (Pubitemid 27090956)
27. Wodarz A and Nusse R: Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14: 59-88, 1998.
28. Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003. (Pubitemid 36627817)
29. Ashihara E, Kawata E, Nakagawa Y, et al: beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 15: 2731-2738, 2009.
30. Gamallo C, Palacios J, Moreno G, et al: beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155: 527-536, 1999. (Pubitemid 29370402)
31. Ysebaert L, Chicanne G, Demur C, et al: Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 20: 1211-1216, 2006. (Pubitemid 43905823)
32. Verma UN, Surabhi RM, Schmaltieg A, et al: Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9: 1291-1300, 2003. (Pubitemid 36418379)
33. Bumcrot D, Manoharan M, Koteliansky V, et al: RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719, 2006. (Pubitemid 44764213)
34. Kawata E, Ashihara E, Nakagawa Y, et al: A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett 294: 245-253, 2010.
35. Feigner PL and Ringold GM: Cationic liposome-mediated transfection. Nature 337: 387-388, 1989.
36. Hirabayashi K, Yano J, Inoue T, et al: Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res 59: 4325-4333, 1999. (Pubitemid 29418751)
37. Sonoke S, Ueda T, Fujiwara K, et al: Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 68: 8843-8851, 2008.
38. Morrissey DV, Lockridge JA, Shaw L, et al: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007, 2005. (Pubitemid 41114035)
39. Zimmermann TS, Lee AC, Akinc A, et al: RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114, 2006.
40. Peer D, Park EJ, Morishita Y, et al: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319: 627-630, 2008. (Pubitemid 351197066)
41. Boussif O, Zanta MA and Behr JP: Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther 3: 1074-1080, 1996. (Pubitemid 27036110)
42. Sano A, Maeda M, Nagahara S, et al: Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev 55: 1651-1677, 2003.
43. Minakuchi Y, Takeshita F, Kosaka N, et al: Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32: e109, 2004.
44. Takei Y, Kadomatsu K, Yuzawa Y, et al: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64: 3365-3370, 2004. (Pubitemid 38657905)
45. Hanai K, Kurokawa T, Minakuchi Y, et al: Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease. Hum Gene Ther 15: 263-272, 2004. (Pubitemid 38365915)
46. Takeshita F, Minakuchi Y, Nagahara S, et al: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102: 12177-12182, 2005. (Pubitemid 41291148)
47. Meade BR and Dowdy SF: Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59: 134-140, 2007. (Pubitemid 46770904)
48. Chiu YL, Ali A, Chu CY, et al: Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 11: 1165-1175, 2004. (Pubitemid 39138769)
49. Soutschek J, Akinc A, Bramlage B, et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178, 2004. (Pubitemid 39545841)
50. Wolfrum C, Shi S, Jayaprakash KN, et al: Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157, 2007. (Pubitemid 47538115)
51. Song E, Zhu P, Lee SK, et al: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717, 2005. (Pubitemid 41716361)
52. Koldehoff M, Steckel NK, Beelen DW, et al: Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7: 47-55, 2007. (Pubitemid 47036743)
53. Bartlett DW and Davis ME: Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng 99: 975-985, 2008. (Pubitemid 351316639)
54. Heidel JD, Yu Z, Liu JY, et al: Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104: 5715-5721, 2007.
55. von Bueren AO, Shalaby T, Oehler-Janne C, et al: RNA interference- mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. BMC Cancer 9: 10, 2009.
56. Elmaagacli AH, Koldehoff M, Peceny R, et al: WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90: 326-334, 2005. (Pubitemid 40388982)
57. Shi XH, Liang ZY, Ren XY, et al: Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 16: 227-236, 2009.